Literature DB >> 24731519

Psychotic Alzheimer's disease is associated with gender-specific tau phosphorylation abnormalities.

Jeremy Koppel1, Chris Acker2, Peter Davies2, Oscar L Lopez3, Heidy Jimenez2, Miriam Azose4, Blaine S Greenwald5, Patrick S Murray3, Caitlin M Kirkwood3, Julia Kofler3, Robert A Sweet6.   

Abstract

Converging evidence suggests that psychotic Alzheimer's disease (AD + P) is associated with an acceleration of frontal degeneration, with tau pathology playing a primary role. Previous histopathologic and biomarker studies have specifically implicated tau pathology in this condition. To precisely quantify tau abnormalities in the frontal cortex in AD + P, we used a sensitive biochemical assay of total tau and 4 epitopes of phospho-tau relevant in AD pathology in a postmortem sample of AD + P and AD - P. Samples of superior frontal gyrus from 26 AD subjects without psychosis and 45 AD + P subjects with psychosis were analyzed. Results of enzyme-linked immunosorbent assay demonstrate that AD + P females, but not males, had significantly higher levels of phosphorylated tau in the frontal cortex. In males, but not females, AD + P was associated with the presence of α-synuclein pathology. These results support a gender dissociation of pathology in AD + P. The design of future studies aimed at the elucidation of cognitive and/or functional outcomes; regional brain metabolic deficits; or genetic correlates of AD + P should take gender into consideration.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alpha-synuclein; Alzheimer's disease; Dementia with Lewy bodies; Neurofibrillary tangles; Psychosis; Tau

Mesh:

Substances:

Year:  2014        PMID: 24731519      PMCID: PMC4155748          DOI: 10.1016/j.neurobiolaging.2014.03.003

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  48 in total

1.  Psychotic symptoms in Alzheimer's disease are not associated with more severe neuropathologic features.

Authors:  R A Sweet; R L Hamilton; O L Lopez; W E Klunk; S R Wisniewski; D I Kaufer; M T Healy; S T DeKosky
Journal:  Int Psychogeriatr       Date:  2000-12       Impact factor: 3.878

2.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease.

Authors:  S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg
Journal:  Neurology       Date:  1991-04       Impact factor: 9.910

Review 3.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.

Authors:  I G McKeith; D Galasko; K Kosaka; E K Perry; D W Dickson; L A Hansen; D P Salmon; J Lowe; S S Mirra; E J Byrne; G Lennox; N P Quinn; J A Edwardson; P G Ince; C Bergeron; A Burns; B L Miller; S Lovestone; D Collerton; E N Jansen; C Ballard; R A de Vos; G K Wilcock; K A Jellinger; R H Perry
Journal:  Neurology       Date:  1996-11       Impact factor: 9.910

Review 4.  Staging of Alzheimer's disease-related neurofibrillary changes.

Authors:  H Braak; E Braak
Journal:  Neurobiol Aging       Date:  1995 May-Jun       Impact factor: 4.673

5.  Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease.

Authors:  P V Arriagada; J H Growdon; E T Hedley-Whyte; B T Hyman
Journal:  Neurology       Date:  1992-03       Impact factor: 9.910

Review 6.  Tau protein and the neurofibrillary pathology of Alzheimer's disease.

Authors:  M Goedert
Journal:  Trends Neurosci       Date:  1993-11       Impact factor: 13.837

7.  Sequential changes of tau-site-specific phosphorylation during development of paired helical filaments.

Authors:  T Kimura; T Ono; J Takamatsu; H Yamamoto; K Ikegami; A Kondo; M Hasegawa; Y Ihara; E Miyamoto; T Miyakawa
Journal:  Dementia       Date:  1996 Jul-Aug

8.  Cognitive deficits of patients with Alzheimer's disease with and without delusions.

Authors:  D V Jeste; R E Wragg; D P Salmon; M J Harris; L J Thal
Journal:  Am J Psychiatry       Date:  1992-02       Impact factor: 18.112

9.  The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease.

Authors:  P N Tariot; J L Mack; M B Patterson; S D Edland; M F Weiner; G Fillenbaum; L Blazina; L Teri; E Rubin; J A Mortimer
Journal:  Am J Psychiatry       Date:  1995-09       Impact factor: 18.112

10.  Late-onset psychosis with somatic delusions.

Authors:  E Rockwell; A J Krull; J Dimsdale; D V Jeste
Journal:  Psychosomatics       Date:  1994 Jan-Feb       Impact factor: 2.386

View more
  18 in total

1.  Lewy Bodies, Vascular Risk Factors, and Subcortical Arteriosclerotic Leukoencephalopathy, but not Alzheimer Pathology, are Associated with Development of Psychosis in Alzheimer's Disease.

Authors:  Corinne E Fischer; Winnie Qian; Tom A Schweizer; Colleen P Millikin; Zahinoor Ismail; Eric E Smith; Lisa M Lix; Paul Shelton; David G Munoz
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

2.  Increased tau phosphorylation follows impeded dopamine clearance in a P301L and novel P301L/COMT-deleted (DM) tau mouse model.

Authors:  Jeremy Koppel; Heidy Jimenez; Leslie Adrien; Eric H Chang; Anil K Malhotra; Peter Davies
Journal:  J Neurochem       Date:  2018-11-12       Impact factor: 5.372

3.  Sex Differences in Neuropathology and Cognitive Behavior in APP/PS1/tau Triple-Transgenic Mouse Model of Alzheimer's Disease.

Authors:  Jun-Ting Yang; Zhao-Jun Wang; Hong-Yan Cai; Li Yuan; Meng-Ming Hu; Mei-Na Wu; Jin-Shun Qi
Journal:  Neurosci Bull       Date:  2018-08-11       Impact factor: 5.203

Review 4.  Animal Models of Psychosis in Alzheimer Disease.

Authors:  Josh M Krivinko; Jeremy Koppel; Alena Savonenko; Robert A Sweet
Journal:  Am J Geriatr Psychiatry       Date:  2019-05-17       Impact factor: 4.105

5.  The neural signatures of psychoses in Alzheimer's disease: a neuroimaging genetics approach.

Authors:  Riccardo Manca; Antonio F Pardiñas; Annalena Venneri
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-06-21       Impact factor: 5.270

Review 6.  Psychosis in Alzheimer disease - mechanisms, genetics and therapeutic opportunities.

Authors:  Zahinoor Ismail; Byron Creese; Dag Aarsland; Helen C Kales; Constantine G Lyketsos; Robert A Sweet; Clive Ballard
Journal:  Nat Rev Neurol       Date:  2022-01-04       Impact factor: 44.711

7.  Altered Levels of Visinin-Like Protein 1 Correspond to Regional Neuronal Loss in Alzheimer Disease and Frontotemporal Lobar Degeneration.

Authors:  Caitlin M Kirkwood; Matthew L MacDonald; Tadhg A Schempf; Anil V Vatsavayi; Milos D Ikonomovic; Jeremy L Koppel; Ying Ding; Mai Sun; Julia K Kofler; Oscar L Lopez; Nathan A Yates; Robert A Sweet
Journal:  J Neuropathol Exp Neurol       Date:  2016-02       Impact factor: 3.685

8.  Alzheimer's disease pathology: pathways between central norepinephrine activity, memory, and neuropsychiatric symptoms.

Authors:  Heidi I L Jacobs; Joost M Riphagen; Inez H G B Ramakers; Frans R J Verhey
Journal:  Mol Psychiatry       Date:  2019-05-28       Impact factor: 15.992

9.  Kalirin reduction rescues psychosis-associated behavioral deficits in APPswe/PSEN1dE9 transgenic mice.

Authors:  Josh M Krivinko; Susan L Erickson; Eric E Abrahamson; Zachary P Wills; Milos D Ikonomovic; Peter Penzes; Robert A Sweet
Journal:  Neurobiol Aging       Date:  2017-02-16       Impact factor: 4.673

Review 10.  Optimal treatment of Alzheimer's disease psychosis: challenges and solutions.

Authors:  Jeremy Koppel; Blaine S Greenwald
Journal:  Neuropsychiatr Dis Treat       Date:  2014-11-24       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.